CLICC day 8 - Inherited cardiomyopathies

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

Please complete the following questions to receive your attendance certificate.

Passing is 5 of 6 correct questions.

You may review the correct answers after submission, and can retake the quiz as many times as needed.

Email *

Full name (for certificate) *

Regarding Mavacamten, all of the following statements are true EXCEPT?

1 point

In the EXPLORER-HCM trial Mavacamten was shown to improve peak oxygen uptake (pVO2) and symptoms in patients with obstructive HCM compared with placebo.

Mavacamten is a cardiac myosin activator.

After initiation of Mavacamten, close monitoring including echocardiography is advised.

Mavacamten has been approved for use by the National Institute for Health and Care Excellence (NICE).

Which of the following are considered gene therapies?

1 point

Gene replacement therapy, direct genome editing, gene silencing.

Monoclonal antibodies, anti-sense oligonucleotides, mRNA vaccines.

Biological therapies, direct genome editing, pharmacogenomics.

Gene replacement therapy, IVF, genetic sequencing.

Gene silencing, next generation sequencing, pre-implantation genetic testing.

In a patient with excessive LV trabeculation, which of the following would NOT be associated with a worse prognosis?

1 point

LBBB on ECG

Subepicardial late gadolinium enhancement on MRI

Mother affected by cardiomyopathy

Non-compacted to compacted layer ratio > 3.5

LVEF 44%

In which of the following is myocarditis NOT a well-recognised clinical presentation?

1 point

Cardiac sarcoid.

Arrhythmogenic cardiomyopathy associated with a DSP pathogenic variant.

COVID-19 infection.

Arrhythmogenic cardiomyopathy associated with a PKP2 pathogenic variant.

Regarding the State of Cardiomyopathy Care Report 2023, all of the following are true EXCEPT?

1 point

There had been an increase in genetic testing for patients with cardiomyopathy compared with the 2019 survey.

The majority of patients with cardiomyopathy struggled to cope emotionally but only a minority were offered mental health support.

The survey found that the majority of patients had a care plan.

The time taken from first seeing a healthcare professional to being diagnosed with cardiomyopathy had increased compared with the 2019 survey.

Which of the following statements is TRUE regarding hTTR Amyloidosis?

1 point

Patisiran is a gene silencing treatment used for polyneuropathy in patients with hTTR Amyloidosis.

hTTR amyloidosis is not associated with carpal tunnel syndrome.

Tafamidis is a TTR stabiliser recommended by the National Institute for Health and Care Excellence for treatment of hTTR amyloidosis with cardiomyopathy.

Cardiac amyloid frequently presents with a dilated cardiomyopathy phenotype.

Overall , how would you rate the session? *

Excellent

Good

Average

Poor

Very poor

Regarding our co chairs, did you have adequate opportunity to ask questions? *

Yes

Regarding our co chairs, do you have any general feedback?

Please rate the speakers using a scale of 1-5 (where 1 = poor and 5 = excellent): *

Brian Halliday

Jane Draper

Paz Tayal

Marianna Fontana

Andrew D'Silva

Amrit Lota

Bethan Cowley

Joel Rose

Stefi Rosmini

Lynne Millar

How did you find the session length? *

Much too long

Too long

About right

Too short

Much too short

What went well?

What could we do better?

Do you have any suggestions for CLICC sessions in 2024?

What motivated you to attend this course?

Clear form

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy

Forms